| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Finance & CFO | SVP, Finance & CFO | SVP Finance & CFO
1 company
Elizabeth L Hougen is EVP, Finance & CFO at IONS. Elizabeth L Hougen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.3M at current prices.
Historically, Elizabeth L Hougen's trades have earned a middling insider score of 61/100 across 11 rated trades. Over a 12-month horizon, 42.9% of those trades were profitable, with an average 12-month return of -20.5%.
The IONS filings lean toward selling, a net 384,056 shares.
Elizabeth L Hougen has 43 Form 4 filings on record from January 2019 to September 2026, across 2 companies: Director at Artiva Biotherapeutics (ARTV), 2025–2026; EVP, Finance & CFO at Ionis Pharmaceuticals (IONS), 2019–2026.
The 88 reported transactions were 24 option or other derivative awards, 24 option exercises, 20 open-market sales and 9 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 15 sales worth about $25.5M.
The largest open-market sale was 225,220 shares of IONS at an average $72.43 on March 17, 2026, about $16.3M.
2 of the 8 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Finance & CFO | Sale+OE10b5-1 | 225,220 | $72.43 | $16,313,675.85 | -73.2% | +2.3% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581,702.08 | -5.0% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Finance & CFO | Sale+OE | 12,922 | $75.22 | $971,992.84 | -9.3% | -1.4% | - | |
| Sep 30, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sale+OE10b5-1 | 49,800 | $65.26 | $3,249,733.86 | -31.1% | +22.3% | -31.7% | |
| Jan 31, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sell | 1,523 | $32.44 | $49,403.68 | -1.4% | -0.6% | +159.2% | |
| Jan 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sale+OE | 8,870 | $32.81 | $290,989.22 | -7.6% | -12.2% | +136.5% | |
| Feb 2, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sell | 2,125 | $49.54 | $105,272.29 | -2.2% | -13.4% | -35.9% | |
| Jan 17, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sale+OE | 8,683 | $50.42 | $437,770.81 | -8.7% | -19.0% | -37.1% | |
| Feb 6, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sell | 2,079 | $40.59 | $84,392.22 | -2.7% | -13.1% | +21.3% | |
| Jan 18, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Finance & CFO | Sale+OE | 8,280 | $39.70 | $328,720.97 | -10.1% | -8.6% | +27.2% |